35.92
price up icon2.25%   0.79
after-market 시간 외 거래: 35.92
loading

Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스

pulisher
Nov 03, 2024

292,569 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Emerald Advisers LLC - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Spyre Therapeutics Announces Grants of Inducement Awards - StockTitan

Nov 01, 2024
pulisher
Oct 30, 2024

Spyre Therapeutics to Participate in Upcoming November Investor Conferences - StockTitan

Oct 30, 2024
pulisher
Oct 29, 2024

Spyre Therapeutics (NASDAQ:SYRE) Price Target Increased to $65.00 by Analysts at Guggenheim - Defense World

Oct 29, 2024
pulisher
Oct 28, 2024

Spyre Therapeutics director sells shares worth $10,929 - Investing.com

Oct 28, 2024
pulisher
Oct 28, 2024

Spyre Therapeutics director sells shares worth $10,929 By Investing.com - Investing.com South Africa

Oct 28, 2024
pulisher
Oct 28, 2024

Jeffrey W. Albers Sells 300 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) Stock - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Spyre Therapeutics' Catalyst Cascade On Track For Late 2024 - RTTNews

Oct 26, 2024
pulisher
Oct 25, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap UpHere's Why - MarketBeat

Oct 25, 2024
pulisher
Oct 25, 2024

Assenagon Asset Management S.A. Acquires New Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Oct 25, 2024
pulisher
Oct 18, 2024

Brokerages Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $43.43 - Defense World

Oct 18, 2024
pulisher
Oct 17, 2024

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 4.5%Time to Buy? - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Results from Spyre Therapeutics Inc. (SYRE) show potential - US Post News

Oct 16, 2024
pulisher
Oct 15, 2024

Wedbush’s latest rating for SYRE stock - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

SYRE’s 2023 Market Dance: Up 42.47% – Time to Invest? - The InvestChronicle

Oct 15, 2024
pulisher
Oct 15, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives $43.43 Consensus PT from Analysts - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Wells Fargo reiterates price target on Spyre shares, optimistic on SPY003 By Investing.com - Investing.com Canada

Oct 15, 2024
pulisher
Oct 14, 2024

Spyre shares rise on positive SPY003 data, analyst maintains Buy By Investing.com - Investing.com UK

Oct 14, 2024
pulisher
Oct 14, 2024

Spyre Therapeutics advances IBD antibody treatments - Investing.com

Oct 14, 2024
pulisher
Oct 14, 2024

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations - PR Newswire

Oct 14, 2024
pulisher
Oct 14, 2024

The Manufacturers Life Insurance Company Takes $888,000 Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Oct 14, 2024
pulisher
Oct 12, 2024

Spyre Therapeutics (SYRE) Price Target Increased by 5.00% to 42.84 - MSN

Oct 12, 2024
pulisher
Oct 09, 2024

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 3.5%Here's Why - MarketBeat

Oct 09, 2024
pulisher
Oct 04, 2024

SYRESpyre Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 04, 2024
pulisher
Oct 03, 2024

Spyre Therapeutics (NASDAQ:SYRE) Trading 2.5% Higher - MarketBeat

Oct 03, 2024
pulisher
Oct 03, 2024

Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter

Oct 03, 2024
pulisher
Oct 02, 2024

Spyre Therapeutics names new Chief Medical Officer By Investing.com - Investing.com South Africa

Oct 02, 2024
pulisher
Oct 01, 2024

Spyre Therapeutics names new Chief Medical Officer - Investing.com

Oct 01, 2024
pulisher
Oct 01, 2024

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting (SYRE) - Seeking Alpha

Oct 01, 2024
pulisher
Oct 01, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Down 7.6% - MarketBeat

Oct 01, 2024
pulisher
Oct 01, 2024

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer - PR Newswire

Oct 01, 2024
pulisher
Sep 30, 2024

Market Watch: Spyre Therapeutics Inc. (SYRE)’s Noteworthy Drop, Closing at 28.49 - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

There is no way Spyre Therapeutics Inc. (SYRE) can keep these numbers up - SETE News

Sep 30, 2024
pulisher
Sep 30, 2024

Recent Insider Activity Suggests Potential Gains for Spyre Therapeutics Inc. (SYRE) - Knox Daily

Sep 30, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Grows Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Sep 30, 2024
pulisher
Sep 29, 2024

687,080 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Driehaus Capital Management LLC - MarketBeat

Sep 29, 2024
pulisher
Sep 29, 2024

Driehaus Capital Management LLC Invests $16.15 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Sep 29, 2024
pulisher
Sep 28, 2024

Ensign Peak Advisors Inc Invests $1.94 Million in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Sep 28, 2024
pulisher
Sep 27, 2024

Armistice Capital LLC Purchases New Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Sep 27, 2024
pulisher
Sep 26, 2024

452,040 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Darwin Global Management Ltd. - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Affinity Asset Advisors LLC Purchases New Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Sep 25, 2024
pulisher
Sep 24, 2024

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

575,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Bought by Logos Global Management LP - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Ratios Uncovered: Breaking Down Spyre Therapeutics Inc. (SYRE)’s Trailing Twelve Months Metrics - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Spyre Therapeutics Inc.’s results are impressive - US Post News

Sep 24, 2024
pulisher
Sep 24, 2024

Great Point Partners LLC Purchases Shares of 134,612 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Integral Health Asset Management LLC Buys New Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Avoro Capital Advisors LLC Purchases Shares of 1,839,138 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Sep 23, 2024
pulisher
Sep 22, 2024

Rhumbline Advisers Purchases Shares of 51,896 Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Sep 22, 2024
pulisher
Sep 21, 2024

Spyre Therapeutics (NASDAQ:SYRE) Trading 4.3% Higher - MarketBeat

Sep 21, 2024
pulisher
Sep 20, 2024

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 4.3% - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Buy" from Analysts - MarketBeat

Sep 20, 2024
pulisher
Sep 19, 2024

Spruce Biosciences Inc’s results are impressive - US Post News

Sep 19, 2024
pulisher
Sep 19, 2024

SciSparc advances phase IIb trial for Tourette Syndrome treatment By Investing.com - Investing.com Australia

Sep 19, 2024
pulisher
Sep 19, 2024

Financial Fitness Check: Examining Spruce Biosciences Inc (SPRB)’s Key Ratios - The Dwinnex

Sep 19, 2024
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
자본화:     |  볼륨(24시간):